Your Messages Inbox
Your Article Summary
See Latest ArticlesRNA Interference Technologies and Therapeutics: From Basic Research to Products
BioDrugs, 09/17/09
Lopez–Fraga M et al. – As with any new technology, several challenges and important aspects to be considered have risen on the road to clinical intervention, e.g. correct design of preclinical toxicology studies, regulatory concerns, and intellectual property protection. The main advantages related to the use of RNAi–based products in a clinical setting, and the latest clinical and preclinical studies using these compounds, are reviewed.
Related Articles
Respiratory Viral RNA on Toys in Pediatric Office Waiting Rooms
The Pediatric Infectious Disease Journal, 11/16/09
Relevance Score: 91%
Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: A cross-sectional study
Journal of Rheumatology, 11/18/09
Relevance Score: 90%
Turnip Mosaic Virus RNA Replication Complex Vesicles Are Mobile, Align with Microfilaments, and Are Each Derived from a Single Viral Genome
Journal of Virology, 10/05/09
Relevance Score: 89%
Replication Mode and Landscape Topology Differentially Affect RNA Virus Mutational Load and Robustness
Journal of Virology, 11/20/09
Relevance Score: 87%
Role of RNA Structures in Genome Terminal Sequences of the Hepatitis C Virus for Replication and Assembly
Journal of Virology, 10/28/09
Relevance Score: 87%
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
Article Search
Sponsor